copd disease

New Novartis Lung Disease Drug Beats GSK's Advair in Study

Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a standard medicine from GlaxoSmithKline.